Gladius Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,400
Closed -$3.47M 71
2026
Q1
$3.13M Buy
+3,400
New +$3.45M 0.14% 81
2025
Q4
Sell
-388
Closed -$371K 107
2025
Q3
$296K Sell
388
-382
-50% -$284K 0.03% 95
2025
Q2
$600K Sell
770
-2,143
-74% -$1.67M 0.22% 48
2025
Q1
$2.41M Sell
2,913
-4,975
-63% -$4.14M 0.64% 40
2024
Q4
$6.09M Buy
7,888
+3,907
+98% +$3.24M 0.65% 33
2024
Q3
$3.53M Buy
3,981
+2,774
+230% +$2.49M 0.43% 43
2024
Q2
$1.09M Buy
1,207
+66
+6% +$52.8K 0.13% 73
2024
Q1
$888K Sell
1,141
-63
-5% -$44.8K 0.29% 75
2023
Q4
$702K Sell
1,204
-1,031
-46% -$602K 0.11% 97
2023
Q3
$1.2M Buy
+2,235
New +$1.15M 0.05% 118
2023
Q2
Sell
-3
Closed -$1.26K 424
2023
Q1
$1.03K Sell
3
-1,218
-100% -$411K ﹤0.01% 367
2022
Q4
$447K Sell
1,221
-572
-32% -$203K 0.03% 103
2022
Q3
$580K Buy
1,793
+1,683
+1,530% +$533K 0.03% 127
2022
Q2
$36K Sell
110
-176
-62% -$52.8K ﹤0.01% 288
2022
Q1
$82K Buy
286
+237
+484% +$61K 0.01% 240
2021
Q4
$14K Buy
+49
New +$12.4K ﹤0.01% 302

Other funds holding LLY

Gladius Capital Management's LLY Position: Q2 2026 in Review

Gladius Capital Management sold out of Eli Lilly (LLY) in Q2 2026, closing a stake of 3,400 shares — an estimated $3.47M sold.

Gladius Capital Management first reported a position in LLY in Q4 2021 and held it in 16 quarters. The position peaked at $6.09M in Q4 2024. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Gladius Capital Management reported no remaining Eli Lilly position as of Q2 2026 after selling out during the quarter.
  • Gladius Capital Management sold 3,400 Eli Lilly shares in Q2 2026, an estimated $3.47M.
  • Gladius Capital Management first reported a position in Eli Lilly in Q4 2021 and held it in 16 quarters.
  • Gladius Capital Management's Eli Lilly position peaked at $6.09M in Q4 2024.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Gladius Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.